Skip to main content

NIAMS Clinical Trial Implementation Cooperative Agreement

Agency: National Institutes of Health

Assistance Listings
  • 93.846 -- Arthritis, Musculoskeletal and Skin Diseases Research

Forecasted opportunityLast Updated: Jun 10, 2026

Important dates

  • Forecasted post date: November 2, 2026
  • Forecasted application due date: July 2, 2027
  • Forecasted award date: April 3, 2028
  • Forecasted project start date: April 3, 2028
  • Fiscal Year: 2028

Award details

  • Expected project funding: Not specified
  • Expected awards: 4

Award min.

$250,000

Award max.

Not specified

  • Funding opportunity number:PAR-28-031
  • Cost sharing or matching requirement:No
  • Funding instrument type:
    • Cooperative agreement
  • Opportunity Category:Discretionary
  • Opportunity Category Explanation:Not specified
  • Category of Funding Activity:
    • Health
  • Category Explanation:Not specified

History

  • Forecast posted date: June 10, 2026
  • Archive date: Not specified
  • Version: 1

View version history on Grants.gov

Summary

The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) intends to publish a Notice of Funding Opportunity (NOFO) to solicit applications for the Clinical Trial Cooperative Agreement Program within the mission areas of the institute.  This Notice of Funding Opportunity (NOFO) solicits cooperative agreement applications for implementation of investigator-initiated, single or multi-site, interventional clinical trials (all trial phases). Investigators who have completed all necessary preparation (e.g., the trial design, protocol synopsis, data analysis plan, etc.) through other means may apply for a NIAMS Cooperative Agreement Clinical Trial. The first phase is designed to allow the investigators to prepare the final aspects needed to start the trial, (e.g., establishing the single IRB (sIRB), contracts and reliance agreements with sites, hiring of staff, etc.). Transition to the second phase to begin the trial is dependent upon completion of the phase 1 milestones proposed by the investigator and approved by NIAMS. Phase 1 projects that meet their milestones will be administratively considered by NIAMS and prioritized for transition to the second phase. NIAMS expects trials to be hypothesis-driven and have the potential for high clinical impact within the research mission of NIAMS.

Eligibility

Miscellaneous

  • Other

Government

  • State governments
  • County governments
  • Public and Indian housing authorities
  • City or township governments
  • Special district governments
  • Federally recognized Native American tribal governments

Education

  • Independent school districts
  • Public and state institutions of higher education
  • Private institutions of higher education

Business

  • For-profit organizations other than small businesses
  • Small businesses

Nonprofit

  • Nonprofits non-higher education without 501(c)(3)
  • Other Native American tribal organizations
  • Nonprofits non-higher education with 501(c)(3)

Additional information on eligibility

Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;Non-domestic (non-U.S.) Entities (Foreign Institutions).

Documents

No documents are currently available.

Agency contact information

Email: NIAMS_NOFOs@mail.nih.gov

NIAMS_NOFOs@mail.nih.gov

National Institute of Arthritis and Musculoskeletal and Skin Diseases Please contact via e-mail.

Link to additional information

No additional information is available

HHS.gov

An official website of the U.S. Department of Health and Human Services

Looking for U.S. government information and services? Visit USA.gov